Summit Therapeu ADR (SMMT)

$18.91 +0.27 (1.45%)
Market Cap 13.88B
Revenue (ttm) 0.00
Net Income (ttm) -221.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,490,300
Avg Vol 4,389,586
Day's Range N/A - N/A
Shares Out 744.44M
Stochastic %K 25%
Beta -1.13
Analysts Strong Sell
Price Target $32.08

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
MoneyGroupLLC
MoneyGroupLLC Nov. 1 at 4:39 AM
Enter: $SMMT Calls Strike Price: $19 Expiry Date: NOV 21 2025 Buy in Price: $1.50 - $1.58 Sell Price: $2.94 Profit : +96% (Turn every $1 into $1.96) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TruthBroker2
TruthBroker2 Oct. 31 at 10:33 PM
$SMMT
0 · Reply
Halbalidiya
Halbalidiya Oct. 31 at 8:55 PM
$SMMT team scummit! Suck an egg!
1 · Reply
charlief
charlief Oct. 31 at 8:40 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Oct. 31 at 8:38 PM
$SMMT
0 · Reply
Ibca1
Ibca1 Oct. 31 at 7:18 PM
$SMMT It feels like no good news can stop SMMT’s decline—the stock is about to crash, plummeting rapidly.
1 · Reply
TruthBroker2
TruthBroker2 Oct. 31 at 3:21 PM
$SMMT
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 3:07 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SMMT Current Share Price: $18.91 Contracts: $SMMT January 15, 2027 $20 Calls Scale in: $7.09- $8.66 Scale out: $11.02-$14.18 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
BooEmmy
BooEmmy Oct. 31 at 2:47 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Oct. 31 at 2:46 PM
$SMMT !
0 · Reply
Latest News on SMMT
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 31, 2025, 7:00 AM EDT - 19 hours ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 9 days ago

Summit Therapeutics Raises $500 Million in Private Placement

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Oct 20, 2025, 5:05 PM EDT - 11 days ago

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 2:35 PM EDT - 11 days ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 10:05 AM EDT - 11 days ago

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 20, 2025, 6:45 AM EDT - 11 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 19, 2025, 10:30 AM EDT - 12 days ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 17, 2025, 7:00 AM EDT - 14 days ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Oct 15, 2025, 7:00 AM EDT - 16 days ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 24, 2025, 4:30 PM EDT - 5 weeks ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 5 weeks ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Ten Bull Market 10-Baggers

Sep 22, 2025, 2:45 PM EDT - 5 weeks ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 6 weeks ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 6 weeks ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 7 weeks ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 7 weeks ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 3:36 PM EDT - 7 weeks ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:28 AM EDT - 7 weeks ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sep 8, 2025, 8:10 AM EDT - 7 weeks ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 7 weeks ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 7 weeks ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 2 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 27, 2025, 2:43 PM EDT - 2 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 2 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 2 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 14, 2025, 3:00 PM EDT - 3 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Jul 4, 2025, 5:10 AM EDT - 4 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 4 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 2:52 PM EDT - 5 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 5 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 2:50 PM EDT - 5 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 5 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 9:01 AM EDT - 5 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 5 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 2, 2025, 1:06 AM EDT - 6 months ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 6 months ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 6 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 28, 2025, 1:00 PM EDT - 6 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 3:14 PM EDT - 6 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 6 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 6 months ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 3:47 PM EDT - 6 months ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 6 months ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Apr 14, 2025, 9:08 AM EDT - 7 months ago

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 24, 2025, 2:17 PM EDT - 7 months ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

MoneyGroupLLC
MoneyGroupLLC Nov. 1 at 4:39 AM
Enter: $SMMT Calls Strike Price: $19 Expiry Date: NOV 21 2025 Buy in Price: $1.50 - $1.58 Sell Price: $2.94 Profit : +96% (Turn every $1 into $1.96) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TruthBroker2
TruthBroker2 Oct. 31 at 10:33 PM
$SMMT
0 · Reply
Halbalidiya
Halbalidiya Oct. 31 at 8:55 PM
$SMMT team scummit! Suck an egg!
1 · Reply
charlief
charlief Oct. 31 at 8:40 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Oct. 31 at 8:38 PM
$SMMT
0 · Reply
Ibca1
Ibca1 Oct. 31 at 7:18 PM
$SMMT It feels like no good news can stop SMMT’s decline—the stock is about to crash, plummeting rapidly.
1 · Reply
TruthBroker2
TruthBroker2 Oct. 31 at 3:21 PM
$SMMT
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 3:07 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SMMT Current Share Price: $18.91 Contracts: $SMMT January 15, 2027 $20 Calls Scale in: $7.09- $8.66 Scale out: $11.02-$14.18 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
BooEmmy
BooEmmy Oct. 31 at 2:47 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Oct. 31 at 2:46 PM
$SMMT !
0 · Reply
Reneejordan001
Reneejordan001 Oct. 31 at 2:20 PM
$SMMT Once the OS is out, the SHORTIES will be burnt to a crisp, well deserved, though....talk about greedy bottom feeders!!
0 · Reply
Expharmaguy
Expharmaguy Oct. 31 at 1:40 PM
$SMMT I am long in SMMT. But the problem here is that this new OS data is in the single region China only, so FDA wants to see the OS benefit in their multi-region phase 3 which included US and Western European patients.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 31 at 1:13 PM
Enter: $SMMT Calls Strike Price: $19 Expiry Date: NOV 21 2025 Buy in Price: $1.50 - $1.90 Sell Price: $3.09 Profit : +106% (Turn every $1 into $2.06) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Reneejordan001
Reneejordan001 Oct. 31 at 12:02 PM
$SMMT No one would have the fortitude to present bad results at this conference!! 👇 https://finance.yahoo.com/news/overall-survival-data-harmoni-featuring-110000111.html
0 · Reply
Snapperhead1988
Snapperhead1988 Oct. 31 at 10:46 AM
$SMMT The job posting for SVP, US Marketing is no longer listed as of today.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 1:08 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SMMT Current Share Price: $18.64 Contracts: $SMMT January 15, 2027 $20 Calls Scale in: $6.82- $8.33 Scale out: $10.61-$13.63 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 30 at 10:03 PM
$SMMT https://oncbrothers.com/wclc-2025
0 · Reply
letstalk8
letstalk8 Oct. 30 at 6:42 PM
$SMMT
0 · Reply
Dilutable
Dilutable Oct. 30 at 5:47 PM
$IXHL This will be a $SMMT.
1 · Reply
letstalk8
letstalk8 Oct. 30 at 5:34 PM
$SMMT Pastor100 is back we are about to moon!!!
0 · Reply
Pastor100
Pastor100 Oct. 30 at 5:04 PM
$SMMT where is the US data after all this time? Keep coming back with the same Chinese data. Maybe it works with that demographic but not the US demographic!
1 · Reply
rangerhawkeye
rangerhawkeye Oct. 30 at 4:57 PM
$SMMT added yesterday 18.97, cmon
0 · Reply